Beyond mRNA vaccines, the 20Med PNP platform is broadly applicable for the intracellular delivery of nucleotide-based payloads.
Our focus is on the development of RNA and DNA based vaccines and therapeutics. Our platform is being applied in several human and animal indications to help accelerate partnered programs towards clinical trials.
Compatible with all types of nucleotide-based payloads such as oligonucleotides and mRNA or DNA
Different routes of administration: intramuscular, intradermal, subcutaneous, intra-tumoral and intra-articular
Wide range of applications
DNA encoded technologies can be an alternative to the well-known mRNA platform. Also, DNA vaccines require a delivery vehicle to target the cytoplasm of cells.
20Med’s polymeric nanoparticle delivery technology has already shown very promising data in delivering DNA-based therapeutic payloads into target cells.
20Med has an ongoing collaboration with Touchlight to improve its novel DNA-vaccine delivery platform.
20Med polymeric nanoparticles can be used for the development of immuno-oncology therapies.
As partner within Oncode-PACT, 20Med is advancing its polymeric Nanoparticle technology for the development of therapeutic cancer vaccines. The aim of therapeutic cancer vaccines is to stimulate the patient´s immune system against specific tumor antigens.
The successful application of mRNA vaccines against COVID-19 has opened the interest for mRNA and DNA vaccines in the veterinary field.
20Med’s polymeric nanoparticle delivery technology has shown very promising preclinical data in delivering RNA and DNA-based therapeutic payloads for veterinary diseases.
20Med has multiple collaborations with veterinary partners.